04:42:24 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandFinland
ListaLarge Cap Helsinki
SektorHälsovård
IndustriMedicinteknik
Revenio är verksamma inom medicinteknik. Inom koncernen återfinns forskning och utveckling av tryckmätningsteknik som används vid behandling av ett flertal sjukdomar som glaukom, osteoporos, hudcancer samt astma. Verksamhet innehas på global nivå och drivs via flertalet dotterbolag med vardera affärsinriktning. Bolagets huvudkontor ligger i Vantaa.

Kalender

2022-10-27 Kvartalsrapport 2022-Q3
2022-08-04 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-11 Ordinarie utdelning REG1V 0.34 EUR
2022-04-08 Årsstämma 2022
2022-02-10 Bokslutskommuniké 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-05 Kvartalsrapport 2021-Q2
2021-04-23 Kvartalsrapport 2021-Q1
2021-03-18 Ordinarie utdelning REG1V 0.32 EUR
2021-03-17 Årsstämma 2021
2021-02-11 Bokslutskommuniké 2020
2020-10-22 Kvartalsrapport 2020-Q3
2020-08-06 Kvartalsrapport 2020-Q2
2020-06-09 Ordinarie utdelning REG1V 0.30 EUR
2020-06-08 Årsstämma 2020
2020-04-22 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-08-15 Kvartalsrapport 2019-Q2
2019-04-16 Kvartalsrapport 2019-Q1
2019-03-21 Ordinarie utdelning REG1V 0.28 EUR
2019-03-20 Årsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-10-25 Kvartalsrapport 2018-Q3
2018-08-06 Kvartalsrapport 2018-Q2
2018-04-20 Kvartalsrapport 2018-Q1
2018-03-21 Ordinarie utdelning REG1V 0.78 EUR
2018-03-20 Årsstämma 2018
2018-02-15 Bokslutskommuniké 2017
2017-10-26 Kvartalsrapport 2017-Q3
2017-08-07 Kvartalsrapport 2017-Q2
2017-05-22 Årsstämma 2017
2017-04-20 Kvartalsrapport 2017-Q1
2017-03-23 Ordinarie utdelning REG1V 0.74 EUR
2017-02-16 Bokslutskommuniké 2016
2016-10-31 Kvartalsrapport 2016-Q3
2016-08-08 Kvartalsrapport 2016-Q2
2016-04-25 Kvartalsrapport 2016-Q1
2016-03-16 Ordinarie utdelning REG1V 0.70 EUR
2016-03-15 Årsstämma 2016
2016-02-15 Bokslutskommuniké 2015
2015-10-27 Kvartalsrapport 2015-Q3
2015-08-10 Kvartalsrapport 2015-Q2
2015-04-24 Kvartalsrapport 2015-Q1
2015-03-20 Ordinarie utdelning REG1V 0.45 EUR
2015-03-19 Årsstämma 2015
2015-02-12 Bokslutskommuniké 2014
2014-10-21 Kvartalsrapport 2014-Q3
2014-08-04 Kvartalsrapport 2014-Q2
2014-04-24 Kvartalsrapport 2014-Q1
2014-03-21 Ordinarie utdelning REG1V 0.30 EUR
2014-03-20 Årsstämma 2014
2014-02-12 Bokslutskommuniké 2013
2013-12-11 Bonusutdelning REG1V 0.3
2013-12-09 Extra Bolagsstämma 2013
2013-10-22 Kvartalsrapport 2013-Q3
2013-08-28 Kapitalmarknadsdag 2013
2013-08-05 Kvartalsrapport 2013-Q2
2013-08-02 Bonusutdelning REG1V 0.12
2013-04-19 Kvartalsrapport 2013-Q1
2013-03-28 Split REG1V 10:1
2013-03-22 Ordinarie utdelning REG1V 0.02 EUR
2013-03-21 Årsstämma 2013
2013-02-08 Bokslutskommuniké 2012
2012-10-19 Kvartalsrapport 2012-Q3
2012-08-06 Kvartalsrapport 2012-Q2
2012-04-19 Kvartalsrapport 2012-Q1
2012-03-29 Ordinarie utdelning REG1V 0.02 EUR
2012-03-28 Årsstämma 2012
2012-02-16 Bokslutskommuniké 2011
2011-10-26 Kvartalsrapport 2011-Q3
2011-08-08 Kvartalsrapport 2011-Q2
2011-04-01 Ordinarie utdelning REG1V 0.02 EUR
2010-04-09 Ordinarie utdelning REG1V 0.01 EUR
2009-04-16 Ordinarie utdelning REG1V 0.02 EUR
2008-04-03 Ordinarie utdelning REG1V 0.04 EUR
2007-04-09 Ordinarie utdelning REG1V 0.01 EUR
2006-03-31 Ordinarie utdelning REG1V 0.00 EUR
2005-04-01 Ordinarie utdelning REG1V 0.00 EUR
2004-03-29 Ordinarie utdelning REG1V 0.00 EUR
2003-03-24 Ordinarie utdelning REG1V 0.00 EUR
2002-04-15 Ordinarie utdelning REG1V 0.00 EUR
2022-04-08 16:00:00

Revenio Group Corporation, Stock Exchange Release, April 8, 2022 at 5.00 p.m. (EEST)

Decisions by the Annual General Meeting of Revenio Group Corporation on April 8, 2022

1. Financial statements, Board and Auditors

The AGM confirmed the company's financial statements for the financial year 1 January – 31 December 2021 and discharged the members of the Board of Directors and the Managing Director from liability.

The AGM decided that five members be elected to the Board of Directors and elected Arne Boye Nielsen, Ann-Christine Sundell, Riad Sherif, Pekka Tammela, and Bill Östman as members of the Board of Directors. In the board meeting held after the AGM, the Board of Directors elected Arne Boye Nielsen as Chair of the Board. The Board of Directors also decided the members of Audit Committee and elected Pekka Tammela, Ann-Christine Sundell and Arne Boye Nielsen. The Board of Directors elected Pekka Tammela as Chair of the Audit Committee. The Board of Directors also decided the members of Nomination and Remuneration Committee and elected Ann-Christine Sundell, Riad Sherif and Bill Östman. The Board of Directors elected Ann-Christine Sundell as Chair of the Nomination and Remuneration Committee.

The AGM decided that the Chairman of the Board be entitled to an annual emolument of EUR 60,000, the Board Members be entitled to an annual emolument of EUR 30,000, the chair of the Audit Committee be entitled to an annual emolument of EUR 15,000, the chair of the Nomination and Remuneration Committee be entitled to an annual emolument of EUR 10,000, and the members of the Board Committees be entitled to an annual emolument of EUR 5,000.

Approximately 40 per cent of the Board members' annual remuneration (gross) will be settled in the form of the company’s shares held in its treasury, however not exceeding a maximum of 3,200 shares in total, while approximately 60 per cent will consist of a monetary payment. Tax will be deducted from the monetary payment, calculated on the amount of the entire annual remuneration. The shares will be assigned to the Board members within two weeks of the release of Revenio Group Corporation’s interim report for the period of 1 January - 31 March 2022, using the trade volume weighted average price on the day following the release of the interim report as the share value.

The AGM further decided that an attendance allowance of EUR 1,000 for members of the Board or Board Committees per Board or Committee meeting and EUR 600 per short teleconference, Board members EUR 600 for Board and Board Committee meetings and EUR 300 for short teleconferences per meeting, yet so that the aforementioned attendance allowance for the Board and Board Committee meetings for Board and Committee chairs who live outside of Finland and travel to Finland for the meeting is EUR 2,000 and the aforementioned attendance allowance for the Board and Board Committee meetings for members is EUR 1,200.

Any travel expenses of the members of the Board or Board Committees will be compensated in accordance with the company’s travel expense regulations.

The AGM re-elected Deloitte Ltd, Authorized Public Accountants, as the company's auditors, with Authorized Public Accountant (KHT) Mikko Lahtinen acting as the principal auditor. The AGM decided to pay the auditors’ fees as invoiced and approved by the company.

2. Annual profit distribution, dividend distribution and capital repayment

The AGM decided to accept the Board's proposal on profit distribution, according to which the parent company’s profit for the financial period, EUR 14,597,451.91, will be added to retained earnings, and a dividend of EUR 0.34 per share will be paid. Dividend will be paid to shareholders who have been registered in the company's shareholder register, maintained by Euroclear Finland Ltd, by the dividend record date on April 12, 2022. The dividend payment date is April 21, 2022.

3. Authorizing the Board of Directors to decide on the acquisition of own shares

The AGM authorized the Board of Directors to resolve on the acquisition or accepting as pledge of a maximum of 1,334,055 of the company’s own shares in one or more tranches using the company’s unrestricted equity. The company may buy back shares in order to develop its capital structure, finance and implement any corporate acquisitions or other transactions, implement share-based incentive plans, pay board fees or otherwise transfer or cancel them.

The company may buy back shares in public trading on marketplaces whose rules and regulations allow the company to trade in its own shares. In such a case, the company buys back shares through a directed purchase, i.e. in a proportion other than its shareholders’ holdings of company shares, with the consideration paid for the shares based on their publicly quoted market price so that the minimum price of the purchased shares equals the lowest market price quoted in public trading during the authorization period and their maximum price equals the highest market price quoted in public trading during that period.

The authorization is effective until the end of the Annual General Meeting held in 2023, yet no further than until June 30, 2023. This authorization supersedes the authorization granted at the Annual General Meeting of March 17, 2021.

4. Authorizing the Board of Directors to decide on a share issue and on granting stock options and other special rights entitling to shares

The AGM decided to authorize the Board of Directors to decide on issuing a maximum of 1,334,055 shares in a share issue or by granting special rights (including stock options) entitling holders to shares as referred to in Chapter 10 Section 1 of the Companies Act, in one or several tranches.

This authorization is to be used to finance and implement any prospective corporate acquisitions or other transactions, to implement the company’s share-based incentive plans, or for other purposes determined by the Board.

The authorization grants the Board the right to decide on all terms and conditions governing the share issue and the granting of said special rights, including on the recipients of the shares or special rights and the amount of payable consideration. The authorization also includes the right to issue shares by deviating from the shareholders’ pre-emptive rights, i.e. in a directed manner. The authorization of the Board covers both the issue of new shares and the assignment of any shares that may be held in the company’s treasury.

The authorization is effective until the end of the Annual General Meeting held in 2023, yet no further than until June 30, 2023. This authorization supersedes the issue authorization granted at the Annual General Meeting of March 17, 2022.

Revenio Group Corporation
Board of Directors

For further information, please contact:
CEO Jouni Toijala, tel. +358 50 484 0085
jouni.toijala@revenio.fi
www.revenio.fi

DISTRIBUTION:
Nasdaq Helsinki
Financial Supervisory Authority (FIN-FSA)
Main media
www.revenio.fi

Revenio Group in brief
Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), perimeter and fundus imaging devices under the iCare brand. In addition, the Group’s eye care software platform Oculo offers clinical communication, telehealth, remote patient monitoring and data analytics capabilities.

In 2021, the Group’s net sales totaled EUR 78.8 million, with an operating profit of EUR 22.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.